Artiva Biotherapeutics, Inc.

ARTVReported to SECin USCIK 0001817241Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 48. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 48
Form 4 lines at Artiva Biotherapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Aslan FredChief Executive OfficerAwardnothing paid315,000 sharesSep 15, 2026Aslan FredChief Executive Officernothing paidAward · Sep 15Award315,000Sep 15, 2026
Aslan FredChief Executive OfficerAwardnothing paid110,000 sharesSep 15, 2026Aslan FredChief Executive Officernothing paidAward · Sep 15Award110,000Sep 15, 2026
RA CAPITAL MANAGEMENT, L.P.—Awardnothing paid16,250 sharesSep 14, 2026RA CAPITAL MANAGEMENT, L.P.nothing paidAward · Sep 14Award16,250Sep 14, 2026
Aslan FredChief Executive OfficerAwardnothing paid155,000 sharesSep 14, 2026Aslan FredChief Executive Officernothing paidAward · Sep 14Award155,000Sep 14, 2026
Aslan FredChief Executive OfficerAwardnothing paid45,000 sharesSep 14, 2026Aslan FredChief Executive Officernothing paidAward · Sep 14Award45,000Sep 14, 2026